Antibodies News and Research

RSS

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

New discovery in Ewing sarcoma may prevent tumor metastasis from occurring

A new discovery in Ewing sarcoma, an aggressive and often fatal childhood cancer, has uncovered the potential to prevent cancer cells from spreading beyond their primary tumor site.

1 Jun 2021

Researchers identify common epitopes across SARS-CoV-2 viral variants

While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.

1 Jun 2021

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a coronavirus disease (COVID-19) treatment.

1 Jun 2021

Using Sotrovimab to treat COVID-19 early

A new study published on the medRxiv* preprint server hypothesized that a monoclonal antibody that has the capability to neutralize all sarbecoviruses could also be used to target a highly conserved epitope. This conserved sequence has a high probability of remaining unchanged in SARS-CoV-2 variants.

31 May 2021

A novel multiplexed diagnostic approach for COVID-19

Researchers developed a platform for detecting the virus directly from a patient's sample as well as the immune response through antibodies such as IgG and IgM.

31 May 2021

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

Researchers at the Department of Viroscience, Erasmus MC, National Institute for Public Health and the Environment, Amsterdam UMC, and the Weill Medical College of Cornell University studied humoral and cellular immune responses to the wild type SARS-CoV-2, the B.1.1.7 variant (U.K. variant) and the B.1.351 variant (South African variant) in health care workers vaccinated with the BNT162b2 (Pfizer-BioNTech) mRNA vaccine.

31 May 2021

Intra-host SARS-CoV-2 composition varies over time, hinting at viral evolution during infection

Researchers at the Southern University of Science and Technology in China revealed rapid and dramatic changes in quasispecies diversity upon evaluating the SARS-CoV-2 populations present in the upper and lower respiratory tracts of patients with varying COVID-19 severity.

31 May 2021

Different early antibody responses define COVID-19 disease trajectory

In a new study posted to the bioRxiv* preprint server, a prospective cohort of patients with COVID-19 exhibited distinct features of the IgG fragment antigen-binding (Fab) and fragment crystallizable (Fc) domains, predicting two distinct disease trajectory two days after a positive test.

31 May 2021

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

A team of scientists from France has recently conducted a study to evaluate the sensitivity of the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to antibody-mediated neutralization.

31 May 2021

Reusing old vaccines to boost innate immunity against COVID-19

The COVID-19 vaccine is currently the best form of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. But a new perspective article published in the journal PNAS suggests it’s not the panacea to stopping SARS-CoV-2.

31 May 2021

Composition and function of gut microbiota are key in affecting immune responses to vaccinations

Varying immune response to vaccinations could be countered with microbiota-targeted interventions helping infants, older people and others to take full advantage of the benefits of effective vaccines, Australian and US experts say.

29 May 2021

Mass screening reveals significantly higher numbers of coeliac disease cases in children

Mass screening of school age children has led to significantly higher numbers of coeliac disease cases being diagnosed, according to a new study presented today at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition.

29 May 2021

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

A new study, published in Nano Letters, describes an effective new COVID-19 vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.

28 May 2021

New SARS-CoV-2 lineages continue to threaten pandemic control in England, suggests genomic study

A new study shows the pattern of the rise of various strains in the UK, as shown by the data collected by the COVID-19 Genomics UK Consortium. This allows the rise and fall of 62 different viral lineages to be traced through over 300 local authorities from September 2020 to April 2021.

28 May 2021

Loss of gut epithelial barrier responsible for COVID-19-related MIS-C in children, suggests study

A new paper in the Journal of Clinical Investigation reports that this condition is due to damage to the gut, mediated by a decrease in the protein called zonulin, which is responsible for the integrity of the gut epithelial barrier. Reduced zonulin levels are found in several inflammatory and autoimmune conditions.

28 May 2021

Researchers identify a novel SARS-CoV-2 variant (with the V1230L mutation) in West Bengal, India

Researchers analyzed 2,000 viral genomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – sequences obtained from India and found a new variant that could be more infectious and transmissible.

28 May 2021

Antibodies News and Research

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

New discovery in Ewing sarcoma may prevent tumor metastasis from occurring

Researchers identify common epitopes across SARS-CoV-2 viral variants

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

Using Sotrovimab to treat COVID-19 early

A novel multiplexed diagnostic approach for COVID-19

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

Intra-host SARS-CoV-2 composition varies over time, hinting at viral evolution during infection

Different early antibody responses define COVID-19 disease trajectory

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

Reusing old vaccines to boost innate immunity against COVID-19

Composition and function of gut microbiota are key in affecting immune responses to vaccinations

Mass screening reveals significantly higher numbers of coeliac disease cases in children

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

New SARS-CoV-2 lineages continue to threaten pandemic control in England, suggests genomic study

Loss of gut epithelial barrier responsible for COVID-19-related MIS-C in children, suggests study

Researchers identify a novel SARS-CoV-2 variant (with the V1230L mutation) in West Bengal, India

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo